1
|
Urie R, Ghosh D, Ridha I, Rege K. Inorganic Nanomaterials for Soft Tissue Repair and Regeneration. Annu Rev Biomed Eng 2018; 20:353-374. [PMID: 29621404 DOI: 10.1146/annurev-bioeng-071516-044457] [Citation(s) in RCA: 41] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
Inorganic nanomaterials have witnessed significant advances in areas of medicine including cancer therapy, imaging, and drug delivery, but their use in soft tissue repair and regeneration is in its infancy. Metallic, ceramic, and carbon allotrope nanoparticles have shown promise in facilitating tissue repair and regeneration. Inorganic nanomaterials have been employed to improve stem cell engraftment in cellular therapy, material mechanical stability in tissue repair, electrical conductivity in nerve and cardiac regeneration, adhesion strength in tissue approximation, and antibacterial capacity in wound dressings. These nanomaterials have also been used to improve or replace common surgical materials and restore functionality to damaged tissue. We provide a comprehensive overview of inorganic nanomaterials in tissue repair and regeneration, and discuss their promise and limitations for eventual translation to the clinic.
Collapse
Affiliation(s)
- Russell Urie
- Department of Chemical Engineering, Arizona State University, Tempe, Arizona 85287-6106, USA;
| | - Deepanjan Ghosh
- Department of Biological Design, Arizona State University, Tempe, Arizona 85287-6106, USA
| | - Inam Ridha
- Department of Biomedical Engineering, Arizona State University, Tempe, Arizona 85287-6106, USA
| | - Kaushal Rege
- Department of Chemical Engineering, Arizona State University, Tempe, Arizona 85287-6106, USA;
| |
Collapse
|
2
|
Cheraghi M, Negahdari B, Daraee H, Eatemadi A. Heart targeted nanoliposomal/nanoparticles drug delivery: An updated review. Biomed Pharmacother 2017; 86:316-323. [DOI: 10.1016/j.biopha.2016.12.009] [Citation(s) in RCA: 23] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/17/2016] [Revised: 12/04/2016] [Accepted: 12/05/2016] [Indexed: 12/23/2022] Open
|
3
|
Evans CW, Iyer KS, Hool LC. The potential for nanotechnology to improve delivery of therapy to the acute ischemic heart. Nanomedicine (Lond) 2016; 11:817-32. [PMID: 26980180 DOI: 10.2217/nnm.16.7] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022] Open
Abstract
Treatment of acute cardiac ischemia remains an area in which there are opportunities for therapeutic improvement. Despite significant advances, many patients still progress to cardiac hypertrophy and heart failure. Timely reperfusion is critical in rescuing vulnerable ischemic tissue and is directly related to patient outcome, but reperfusion of the ischemic myocardium also contributes to damage. Overproduction of reactive oxygen species, initiation of an inflammatory response and deregulation of calcium homeostasis all contribute to injury, and difficulties in delivering a sufficient quantity of drug to the affected tissue in a controlled manner is a limitation of current therapies. Nanotechnology may offer significant improvements in this respect. Here, we review recent examples of how nanoparticles can be used to improve delivery to the ischemic myocardium, and suggest some approaches that may lead to improved therapies for acute cardiac ischemia.
Collapse
Affiliation(s)
- Cameron W Evans
- School of Chemistry & Biochemistry, The University of Western Australia, 35 Stirling Hwy, Crawley, WA 6009, Australia
| | - K Swaminathan Iyer
- School of Chemistry & Biochemistry, The University of Western Australia, 35 Stirling Hwy, Crawley, WA 6009, Australia
| | - Livia C Hool
- School of Anatomy, Physiology & Human Biology, The University of Western Australia, 35 Stirling Hwy, Crawley, WA 6009, Australia.,Victor Chang Cardiac Research Institute, 405 Liverpool St, Darlinghurst, NSW 2010, Australia
| |
Collapse
|
4
|
Abstract
Nanotechnology is a multidisciplinary field that covers a vast and diverse array of devices derived from physics, biology, engineering, and chemistry. Applications of nanotechnology to medicine and physiology imply materials and devices designed to interact with the body at subcellular (i.e., molecular) scales with a high degree of specificity. There is considerable useful information about nanotechnology available and already in use. However, at present, it is very incomplete and scattered. We realized many doctors are unaware of nanotechnology used during surgery and its future prospects in patients. Though most medical products that use nanotechnology are still in the research and development stage, there are a few which are commercially available. Nanotechnology has grown by leaps and bounds over the last few years; applications of this technology in the field of medicine and surgery have been an important spin-off. Many biological structures are at nanometer scale used by surgeons in orthopedic, dental, and neurosurgeries. This article starts with the basics of the nanotechnology and how it is utilized through most medical products. This important article, which is felt to offer high educational value for the doctors, have been selected from an extensive search on the internet, and elaborately discussed. In this review, the scientific and technical aspects of nanotechnology are introduced, and some of its potential clinical applications are discussed.
Collapse
Affiliation(s)
- Sanjeev Singh
- Department of Anaesthesia and Intensive Care, School of Medical Sciences, College of Health Sciences, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana, West Africa ; NHIMS, Department of Cardiac Anaesthesia, Bangalore, India
| | - Arti Singh
- Department of Public health, KNUST Hospital, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana, West Africa
| |
Collapse
|
5
|
Spivak MY, Bubnov RV, Yemets IM, Lazarenko LM, Tymoshok NO, Ulberg ZR. Gold nanoparticles - the theranostic challenge for PPPM: nanocardiology application. EPMA J 2013; 4:18. [PMID: 23800174 PMCID: PMC3702527 DOI: 10.1186/1878-5085-4-18] [Citation(s) in RCA: 34] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/03/2013] [Accepted: 06/13/2013] [Indexed: 12/18/2022]
Abstract
The article overviews the potential biomedical applications of nanoscale gold particles for predictive, preventive and personalised nanomedicine in cardiology. The review demonstrates the wide opportunities for gold nanoparticles due to their unique biological properties. The use of gold nanoparticles in cardiology is promising to develop fundamentally new methods of diagnosis and treatment. The nanotheranostics in cardiovascular diseases allows the non-invasive imaging associated with simultaneous therapeutic intervention and predicting treatment outcomes. Imaging may reflect the effectiveness of treatment and has become a fundamental optimisation setting for therapeutic protocol. Combining the application of biomolecular and cellular therapies with nanotechnologies foresees the development of complex integrated nanodevices. Nanocardiology may challenge existing healthcare system and economic benefits as cardiovascular diseases are the leading cause of morbidity and mortality at present.
Collapse
Affiliation(s)
- Mykola Ya Spivak
- Zabolotny Institute of Microbiology and Virology, National Academy of Sciences of Ukraine, Zabolotny Str., 154, Kyiv 03680, Ukraine
- LCL “DIAPROF”, Svitlycky Str., 35, Kyiv 04123, Ukraine
| | - Rostyslav V Bubnov
- Zabolotny Institute of Microbiology and Virology, National Academy of Sciences of Ukraine, Zabolotny Str., 154, Kyiv 03680, Ukraine
- Clinical Hospital “Pheophania” of State Affairs Department, Zabolotny Str., 21, Kyiv 03680, Ukraine
| | - Ilya M Yemets
- Scientific-Practical Centre of Pediatric Cardiology and Cardiac Health of Ukraine, Chornovil Str., 28/1, Kyiv 01135, Ukraine
| | - Liudmyla M Lazarenko
- Zabolotny Institute of Microbiology and Virology, National Academy of Sciences of Ukraine, Zabolotny Str., 154, Kyiv 03680, Ukraine
| | - Natalia O Tymoshok
- Zabolotny Institute of Microbiology and Virology, National Academy of Sciences of Ukraine, Zabolotny Str., 154, Kyiv 03680, Ukraine
| | - Zoia R Ulberg
- Ovcharenko Institute of Biocolloidal Chemistry, National Academy of Sciences of Ukraine, Acad. Vernadsky Blvd, 42, Kyiv 03142, Ukraine
| |
Collapse
|
6
|
Monsky WL, Vien DS, Link DP. Nanotechnology Development and Utilization: A Primer for Diagnostic and Interventional Radiologists. Radiographics 2011; 31:1449-62. [DOI: 10.1148/rg.315105238] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
|
7
|
Nanotechnology and its Relationship to Interventional Radiology. Part II: Drug Delivery, Thermotherapy, and Vascular Intervention. Cardiovasc Intervent Radiol 2010; 34:676-90. [DOI: 10.1007/s00270-010-9967-y] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/04/2010] [Accepted: 07/22/2010] [Indexed: 01/26/2023]
|
8
|
Godin B, Sakamoto JH, Serda RE, Grattoni A, Bouamrani A, Ferrari M. Emerging applications of nanomedicine for the diagnosis and treatment of cardiovascular diseases. Trends Pharmacol Sci 2010; 31:199-205. [PMID: 20172613 PMCID: PMC2862836 DOI: 10.1016/j.tips.2010.01.003] [Citation(s) in RCA: 141] [Impact Index Per Article: 10.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/06/2009] [Revised: 01/25/2010] [Accepted: 01/26/2010] [Indexed: 01/12/2023]
Abstract
Nanomedicine is an emerging field that utilizes nanotechnology concepts for advanced therapy and diagnostics. This convergent discipline merges research areas such as chemistry, biology, physics, mathematics and engineering. It therefore bridges the gap between molecular and cellular interactions, and has the potential to revolutionize medicine. This review presents recent developments in nanomedicine research poised to have an important impact on the treatment of cardiovascular disease. This will occur through improvement of the diagnosis and therapy of cardiovascular disorders as atherosclerosis, restenosis and myocardial infarction. Specifically, we discuss the use of nanoparticles for molecular imaging and advanced therapeutics, specially designed drug eluting stents and in vivo/ex vivo early detection techniques.
Collapse
Affiliation(s)
- Biana Godin
- University of Texas Health Science Center at Houston (UTHSC-H), Department of NanoMedicine and Biomedical Engineering, 1825 Pressler, Suite 537, Houston, TX 77030
| | - Jason H. Sakamoto
- University of Texas Health Science Center at Houston (UTHSC-H), Department of NanoMedicine and Biomedical Engineering, 1825 Pressler, Suite 537, Houston, TX 77030
| | - Rita E. Serda
- University of Texas Health Science Center at Houston (UTHSC-H), Department of NanoMedicine and Biomedical Engineering, 1825 Pressler, Suite 537, Houston, TX 77030
| | - Alessandro Grattoni
- University of Texas Health Science Center at Houston (UTHSC-H), Department of NanoMedicine and Biomedical Engineering, 1825 Pressler, Suite 537, Houston, TX 77030
| | - Ali Bouamrani
- University of Texas Health Science Center at Houston (UTHSC-H), Department of NanoMedicine and Biomedical Engineering, 1825 Pressler, Suite 537, Houston, TX 77030
| | - Mauro Ferrari
- University of Texas Health Science Center at Houston (UTHSC-H), Department of NanoMedicine and Biomedical Engineering, 1825 Pressler, Suite 537, Houston, TX 77030
- University of Texas MD Anderson Cancer Center, Department of Experimental Therapeutics, Unit 422, 1515 Holcombe Blvd., Houston, TX 77030
- Rice University, Department of Bioengineering, Houston, TX 77005
| |
Collapse
|
9
|
Lukyanenko V. Delivery of nano-objects to functional sub-domains of healthy and failing cardiac myocytes. Nanomedicine (Lond) 2008; 2:831-46. [PMID: 18095849 DOI: 10.2217/17435889.2.6.831] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023] Open
Abstract
Cardiovascular disease, including heart failure, is one of the leading causes of mortality in the world. Delivery of nano-objects as carriers for markers, drugs or therapeutic genes to cellular organelles has the potential to sharply increase the efficiency of diagnostic and treatment protocols for heart failure. However, cardiac cells present special problems to the delivery of nano-objects, and the number of papers devoted to this important area is remarkably small. The present review discusses fundamental aspects, problems and perspectives in the delivery of nano-objects to functional sub-domains of failing cardiomyocytes. What size nano-objects can reach cellular sub-domains in failing hearts? What are the mechanisms for their permeation through the sarcolemma? How can we improve the delivery of nano-objects to the sub-domains? Answering these questions is fundamental to identifying cellular targets within the failing heart and the development of nanocarriers for heart-failure therapy at the cellular level.
Collapse
Affiliation(s)
- Valeriy Lukyanenko
- University of Maryland Biotechnology Institute, Medical Biotechnology Center, 725 W. Lombard St., Rm S216, Baltimore, MD 21201, USA.
| |
Collapse
|
10
|
Faunce TA. Challenges for Australia's Bio/Nanopharma Policies: trade deals, public goods and reference pricing in sustainable industrial renewal. AUSTRALIA AND NEW ZEALAND HEALTH POLICY 2007; 4:9. [PMID: 17543114 PMCID: PMC1894805 DOI: 10.1186/1743-8462-4-9] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Received: 10/18/2006] [Accepted: 06/01/2007] [Indexed: 11/21/2022]
Abstract
Industrial renewal in the bio/nanopharma sector is important for the long term strength of the Australian economy and for the health of its citizens. A variety of factors, however, may have caused inadequate attention to focus on systematically promoting domestic generic and small biotechnology manufacturers in Australian health policy. Despite recent clarifications of 'springboarding' capacity in intellectual property legislation, federal government requirements for specific generic price reductions on market entry and the potential erosion of reference pricing through new F1 and F2 categories for the purposes of Pharmaceutical Benefits Scheme (PBS) assessments, do not appear to be coherently designed to sustainably position this industry sector in 'biologics,' nanotherapeutics and pharmacogenetics. There also appears to have been little attention paid in this context to policies fostering industry sustainability and public affordability (as encouraged by the National Medicines Policy). One notable example includes that failure to consider facilitating mutual exchanges on regulatory assessment of health technology safety and cost-effectiveness (including reference pricing) in the context of ongoing free trade negotiations between Australia and China (the latter soon to possess the world's largest generic pharmaceutical manufacturing capacity). The importance of a thriving Australian domestic generic pharmaceutical and bio/nano tech industry in terms of biosecurity, similarly appears to have been given insufficient policy attention.Reasons for such policy oversights may relate to increasing interrelationships between generic and 'brand-name' manufacturers and the scale of investment required for the Australian generics and bio/nano technology sector to be a significant driver of local production. It might also result from singularly effective lobbying pressure exerted by Medicines Australia, the 'brand-name' pharmaceutical industry association, utilising controversial interpretations of reward of pharmaceutical 'innovation' provisions in the Australia-US Free Trade Agreement (AUSFTA) through the policy-development mechanisms of the AUSFTA Medicines Working Group and most recently an Innovative Medicines Working Group with the Department of Health and Ageing. This paper critically analyses such arguments in the context of emerging challenges for sustainable industrial renewal in Australia's bio/nanopharma sector.
Collapse
Affiliation(s)
- Thomas A Faunce
- College of Law and Medical School, Australian National University, Canberra, Australia.
| |
Collapse
|
11
|
The present and future of nanotechnology in human health care. NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE 2007; 3:20-31. [PMID: 17379166 DOI: 10.1016/j.nano.2006.11.008] [Citation(s) in RCA: 361] [Impact Index Per Article: 21.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/03/2006] [Revised: 10/04/2006] [Accepted: 11/21/2006] [Indexed: 12/13/2022]
Abstract
Nanotechnology is a multidisciplinary field that covers a vast and diverse array of devices derived from engineering, physics, chemistry, and biology. The burgeoning new field of nanotechnology, opened up by rapid advances in science and technology, creates myriad new opportunities for advancing medical science and disease treatment in human health care. Applications of nanotechnology to medicine and physiology imply materials and devices designed to interact with the body at subcellular (i.e., molecular) scales with a high degree of specificity. This can be potentially translated into targeted cellular and tissue-specific clinical applications designed to achieve maximal therapeutic efficacy with minimal side effects. In this review the chief scientific and technical aspects of nanotechnology are introduced, and some of its potential clinical applications are discussed.
Collapse
|
12
|
Faunce TA. Nanotechnology in global medicine and human biosecurity: private interests, policy dilemmas, and the calibration of public health law. THE JOURNAL OF LAW, MEDICINE & ETHICS : A JOURNAL OF THE AMERICAN SOCIETY OF LAW, MEDICINE & ETHICS 2007; 35:629-512. [PMID: 18076514 DOI: 10.1111/j.1748-720x.2007.00186.x] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/25/2023]
Abstract
This paper considers how best to approach dilemmas posed to global health and biosecurity policy by increasing advances in practical applications of nanotechnology. The type of nano-technology policy dilemmas discussed include: (1) expenditure of public funds, (2) public-funded research priorities, (3) public confidence in government and science and, finally, (4) public safety. The article examines the value in this context of a legal obligation that the development of relevant public health law be calibrated against less corporate-influenced norms issuing from bioethics and international human rights.
Collapse
Affiliation(s)
- Thomas A Faunce
- College of Law and Medical School at the Australian National University
| |
Collapse
|
13
|
Faunce TA, Walters H, Williams T, Bryant D, Jennings M, Musk B. Policy challenges from the "White" Senate inquiry into workplace-related health impacts of toxic dusts and nanoparticles. AUSTRALIA AND NEW ZEALAND HEALTH POLICY 2006; 3:7. [PMID: 16780594 PMCID: PMC1513237 DOI: 10.1186/1743-8462-3-7] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Received: 11/03/2005] [Accepted: 06/17/2006] [Indexed: 11/12/2022]
Abstract
On 22 June 2005 the Senate of the Commonwealth of Australia voted to establish an inquiry into workplace harm related to toxic dust and emerging technologies (including nanoparticles). The inquiry became known as the "White" Inquiry after Mr Richard White, a financially uncompensated sufferer of industrial sandblasting-induced lung disease who was instrumental in its establishment. The "White" Inquiry delivered its final report and recommendations on 31 May 2006. This paper examines whether these recommendations and their implementation may provide a unique opportunity not only to modernize relevant monitoring standards and processes, but related compensation systems for disease associated with workplace-related exposure to toxic dusts. It critically analyzes the likely role of the new Australian Safety and Compensation Council (ASCC) in this area. It also considers whether recommendations related to potential workplace related harm from exposure to nanoparticles could commence a major shift in Australian healthcare regulation.
Collapse
Affiliation(s)
- Thomas A Faunce
- Medical School and College of Law Australian National University, Canberra, Australia
| | - Haydn Walters
- Royal Hobart Hospital, Clinical School University of Tasmania, Hobart, Australia
| | - Trevor Williams
- Department of Allergy, Immunology & Respiratory Medicine, The Alfred Hospital, Melbourne, Australia
| | - David Bryant
- Department of Medicine St Vincent's Clinical School and University of NSW, Sydney, Australia
| | - Martin Jennings
- Past President Australian Institute of Occupational Hygenists, Australia
| | - Bill Musk
- Faculty of Public Health and Medicine University of Western Australia, Perth, Australia
| |
Collapse
|